June 8, 2020
Pharmaceutical and biotechnology companies around the world are rising to the challenges presented by the COVID-19 pandemic. In a new book, Biotechnology in the Time of COVID-19: Commentaries from the Front Line, more than forty leaders share their perspectives and personal stories about what this moment means for our industry, the novel ways in which companies are collaborating and how our collective response can impact humanity.
Takeda’s President of R&D, Andy Plump, contributed his reflections on how our values are guiding our pandemic response, the importance of engaging internally with employees and the fundamental changes we can expect to see across the continnuum of drug discovery and development as result. Read the full text of Andy’s chapter.
The e-book is available for free download globally June 8-12, 2020 through the Amazon Kindle store.
Following the free download period, the book editor and publisher have committed to donating a majority of the proceeds from the sale of Biotechnology in the Time of COVID-19: Commentaries from the Front Line will be donated to Global Genes and The Institute for Life Changing Medicines.